Influences of follicle-stimulating hormone, proteases, and antiproteases on permeability of the barrier generated by Sertoli cells in a two-chambered assembly.
Factors have been identified that influence the integrity of the barrier generated by Sertoli cells (SC) in culture in a two-chambered assembly. The permeability of the barrier was assessed by determining rates of equilibration of [3H]methoxyinulin or [86Rb]Cl across the Sertoli cell monolayer. The complete system consisted of a confluent monolayer of SC maintained on an extracellular matrix (Matrigel)-coated filter together with peritubular cells on the opposite side of the filter. In confirmation of previous results, levels of plasminogen activator (PA) activity secreted were increased by treatment of SC with FSH or with cAMP derivatives [(Bu)2cAMP (dbcAMP)]. PA levels in the culture medium were inversely related to times required for 50% equilibration of [3H]methoxyinulin across the SC monolayer. Thus, elevated PA levels, elicited by stimulation with FSH or dbcAMP, were associated with a decreased integrity of the barrier generated by SC preparations maintained in serum-free medium in the complete system. The increase in permeability of the barrier in SC elicited by FSH dbcAMP could be prevented, however, by the addition of various antiproteases. FSH actions on barrier function were complex. Effects of FSH that favored barrier integrity were most readily detected when proteolytic activity was inhibited. The addition of intact serum increased the integrity of the barrier, but acid-treated serum depleted of antiproteases had no such effect. We advance the hypothesis that proteases are implicated in modulation of the formation and maintenance of the seminiferous tubule barrier by SC.
Ailenberg
M
M
Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada.
Fritz
I B
IB
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D001769:Blood; D003994:Bucladesine / Q000494:pharmacology; D002463:Cell Membrane Permeability / Q000187:drug effects*; D002478:Cells, Cultured; D002712:Chlorides / Q000378:metabolism; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007444:Inulin / Q000031:analogs & derivatives / Q000378:metabolism; D008297:Male; D008855:Microscopy, Electron, Scanning; D010447:Peptide Hydrolases / Q000378:metabolism* / Q000494:pharmacology; D010960:Plasminogen Activators / Q000378:metabolism; D011480:Protease Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D012413:Rubidium / Q000378:metabolism; D012414:Rubidium Radioisotopes; D012708:Sertoli Cells / Q000378:metabolism* / Q000648:ultrastructure
D002712:Chlorides; D011480:Protease Inhibitors; D012414:Rubidium Radioisotopes; D003994:Bucladesine; C036740:methoxyinulin; D005640:Follicle Stimulating Hormone; D007444:Inulin; D010447:Peptide Hydrolases; D010960:Plasminogen Activators; D012413:Rubidium; C032710:rubidium chloride; D015056:1-Methyl-3-isobutylxanthine